Sudhir Manda, MD of Arizona Oncology discusses the long-term proteasome inhibition in multiple myeloma following an in-class transition from bortezomib to ixazomib.
Sudhir Manda, MD on Proteasome Inhibition in MM: Who is Eligible?
Sudhir Manda, MD of Arizona Oncology discusses the long-term proteasome inhibition in multiple myeloma following an in-class transition from bortezomib to ixazomib.